The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.
All participants will be phenotype and participants will randomized to randomly assigned medications vs phenotype guided medications for obesity. All participants will receive a standard intense lifestyle intervention.All participants will be seen at 4 and 12 weeks. At the 12-week visit, participants will be unblinded to their "obesity-related phenotype" and they could contact their physician to continue a FDA-approved medication as part of clinical care. Study team will prospectively follow the patients' weight, waist circumference and use of obesity medications every 3 months for 1 year.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
193
Extended Release at dose of 7.5/46 mg oral daily
dose of 3 mg subcutaneous daily
Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Change in Total Body Weight
Percent change in body weight
Time frame: baseline to 12 weeks
Percentage of Responders
Percentage of participants who loss 5% or more of total body weight
Time frame: baseline to 12 weeks
Percentage of Responders
Percentage of participants with at least 10% total body weight loss
Time frame: baseline to 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
15-37.5 mg oral daily